|
1
|
Moore N and Lyle S: Quiescent,
slow-cycling stem cell populations in cancer: A review of the
evidence and discussion of significance. J Oncol.
pii:3960762011.
|
|
2
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tirino V, Desiderio V, Paino F, De Rosa A,
Papaccio F, La Noce M, Laino L, De Francesco F and Papaccio G:
Cancer stem cells in solid tumors: An overview and new approaches
for their isolation and characterization. FASEB J. 27:13–24. 2013.
View Article : Google Scholar
|
|
4
|
Li L and Bhatia R: Stem cell quiescence.
Clin Cancer Res. 17:4936–4941. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dontu G, Abdallah WM, Foley JM, Jackson
KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and
transcriptional profiling of human mammary stem/progenitor cells.
Genes Dev. 17:1253–1270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Farnie G, Clarke RB, Spence K, Pinnock N,
Brennan K, Anderson NG and Bundred NJ: Novel cell culture technique
for primary ductal carcinoma in situ: Role of Notch and epidermal
growth factor receptor signaling pathways. J Natl Cancer Inst.
99:616–627. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grimshaw MJ, Cooper L, Papazisis K,
Coleman JA, Bohnenkamp HR, Chiapero-Stanke L, Taylor-Papadimitriou
J and Burchell JM: Mammosphere culture of metastatic breast cancer
cells enriches for tumorigenic breast cancer cells. Breast Cancer
Res. 10:R522008. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ponti D, Costa A, Zaffaroni N, Pratesi G,
Petrangolini G, Coradini D, Pilotti S, Pierotti MA and Daidone MG:
Isolation and in vitro propagation of tumorigenic breast cancer
cells with stem/progenitor cell properties. Cancer Res.
65:5506–5511. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim S and Alexander CM: Tumorsphere assay
provides more accurate prediction of in vivo responses to
chemotherapeutics. Biotechnol Lett. 36:481–488. 2014. View Article : Google Scholar :
|
|
10
|
Reis-Filho JS and Tutt AN: Triple negative
tumours: A critical review. Histopathology. 52:108–118. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lund MJ, Trivers KF, Porter PL, Coates RJ,
Leyland-Jones B, Brawley OW, Flagg EW, O’Regan RM, Gabram SG and
Eley JW: Race and triple negative threats to breast cancer
survival: A population-based study in Atlanta, GA. Breast Cancer
Res Treat. 113:357–370. 2009. View Article : Google Scholar
|
|
12
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Isakoff SJ: Triple-negative breast cancer:
Role of specific chemotherapy agents. Cancer J. 16:53–61. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shaw FL, Harrison H, Spence K, Ablett MP,
Simões BM, Farnie G and Clarke RB: A detailed mammosphere assay
protocol for the quantification of breast stem cell activity. J
Mammary Gland Biol Neoplasia. 17:111–117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim S, Chun SY, Lee DH, Lee KS and Nam KS:
Mineral-enriched deep-sea water inhibits the metastatic potential
of human breast cancer cell lines. Int J Oncol. 43:1691–1700.
2013.PubMed/NCBI
|
|
16
|
Karukstis KK, Thompson EH, Whiles JA and
Rosenfeld RJ: Deciphering the fluorescence signature of daunomycin
and doxorubicin. Biophys Chem. 73:249–263. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shen F, Chu S, Bence AK, Bailey B, Xue X,
Erickson PA, Montrose MH, Beck WT and Erickson LC: Quantitation of
doxorubicin uptake, efflux, and modulation of multidrug resistance
(MDR) in MDR human cancer cells. J Pharmacol Exp Ther. 324:95–102.
2008. View Article : Google Scholar
|
|
18
|
Calvet CY, André FM and Mir LM: The
culture of cancer cell lines as tumorspheres does not
systematically result in cancer stem cell enrichment. PLoS One.
9:e896442014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pastrana E, Silva-Vargas V and Doetsch F:
Eyes wide open: A critical review of sphere-formation as an assay
for stem cells. Cell Stem Cell. 8:486–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guttilla IK, Phoenix KN, Hong X, Tirnauer
JS, Claffey KP and White BA: Prolonged mammosphere culture of MCF-7
cells induces an EMT and repression of the estrogen receptor by
microRNAs. Breast Cancer Res Treat. 132:75–85. 2012. View Article : Google Scholar
|
|
21
|
Manuel Iglesias J, Beloqui I,
Garcia-Garcia F, Leis O, Vazquez-Martin A, Eguiara A, Cufi S, Pavon
A, Menendez JA, Dopazo J, et al: Mammosphere formation in breast
carcinoma cell lines depends upon expression of E-cadherin. PLoS
One. 8:e772812013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Uchida Y, Tanaka S, Aihara A, Adikrisna R,
Yoshitake K, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Irie
T, et al: Analogy between sphere forming ability and stemness of
human hepatoma cells. Oncol Rep. 24:1147–1151. 2010.PubMed/NCBI
|
|
23
|
Grant S, Qiao L and Dent P: Roles of ERBB
family receptor tyrosine kinases, and downstream signaling
pathways, in the control of cell growth and survival. Front Biosci.
7:d376–d389. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Normanno N, De Luca A, Bianco C, Strizzi
L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F and
Salomon DS: Epidermal growth factor receptor (EGFR) signaling in
cancer. Gene. 366:2–16. 2006. View Article : Google Scholar
|
|
25
|
Corkery B, Crown J, Clynes M and O’Donovan
N: Epidermal growth factor receptor as a potential therapeutic
target in triple-negative breast cancer. Ann Oncol. 20:862–867.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baselga J, Albanell J, Ruiz A, Lluch A,
Gascón P, Guillém V, González S, Sauleda S, Marimón I, Tabernero
JM, et al: Phase II and tumor pharmacodynamic study of gefitinib in
patients with advanced breast cancer. J Clin Oncol. 23:5323–5333.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dickler MN, Cobleigh MA, Miller KD, Klein
PM and Winer EP: Efficacy and safety of erlotinib in patients with
locally advanced or metastatic breast cancer. Breast Cancer Res
Treat. 115:115–121. 2009. View Article : Google Scholar
|
|
28
|
Coley HM, Shotton CF, Ajose-Adeogun A,
Modjtahedi H and Thomas H: Receptor tyrosine kinase (RTK)
inhibition is effective in chemosensitising EGFR-expressing drug
resistant human ovarian cancer cell lines when used in combination
with cytotoxic agents. Biochem Pharmacol. 72:941–948. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Molina JR, Kaufmann SH, Reid JM, Rubin SD,
Gálvez-Peralta M, Friedman R, Flatten KS, Koch KM, Gilmer TM,
Mullin RJ, et al: Evaluation of lapatinib and topotecan combination
therapy: Tissue culture, murine xenograft, and phase I clinical
trial data. Clin Cancer Res. 14:7900–7908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mukherjee A, Dhadda AS, Shehata M and Chan
S: Lapatinib: A tyrosine kinase inhibitor with a clinical role in
breast cancer. Expert Opin Pharmacother. 8:2189–2204. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR,
Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, et al: Lapatinib
(Tykerb, GW572016) reverses multidrug resistance in cancer cells by
inhibiting the activity of ATP-binding cassette subfamily B member
1 and G member 2. Cancer Res. 68:7905–7914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Perry J, Ghazaly E, Kitromilidou C,
McGrowder EH, Joel S and Powles T: A synergistic interaction
between lapatinib and chemotherapy agents in a panel of cell lines
is due to the inhibition of the efflux pump BCRP. Mol Cancer Ther.
9:3322–3329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shukla S, Chen ZS and Ambudkar SV:
Tyrosine kinase inhibitors as modulators of ABC
transporter-mediated drug resistance. Drug Resist Updat. 15:70–80.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dean M: ABC transporters, drug resistance,
and cancer stem cells. J Mammary Gland Biol Neoplasia. 14:3–9.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Higgins CF: ABC transporters: From
microorganisms to man. Annu Rev Cell Biol. 8:67–113. 1992.
View Article : Google Scholar : PubMed/NCBI
|
